Omburtamab is a Monoclonal Antibody Conjugated owned by Y-mAbs Therapeutics, and is involved in 10 clinical trials, of which 3 were completed, 6 are ongoing, and 1 is planned.
Monoclonal antibody conjugate elicits anticancer activity. B7H3 (CD276) is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). the therapeutic candidate inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4 and exhibits therapeutic intervention.
The revenue for Omburtamab is expected to reach a total of $4.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Omburtamab NPV Report.
Omburtamab was originated by Memorial Sloan Kettering Cancer Center and is currently owned by Y-mAbs Therapeutics. SciClone Pharmaceuticals Holdings is the other company associated in development or marketing of Omburtamab.
Monoclonal antibody conjugate is under development for the treatment of refractory central nervous system (brain) tumor, atypical teratoid rhabdoid tumor, leptomeningeal neoplasms, neuroblastoma metastatic, adrenocortical carcinoma, ependymoma, sarcomas, melanoma, medulloblastoma, primitive neuroectodermal tumor (PNET), pediatric diffuse intrinsic pontine glioma, desmoplastic small round cell tumor of peritoneum and Wilms' tumor. It is administered through intrathecal, intraperitoneal and intracerebroventricular routes. The monoclonal antibody 8H9 is an IgG1 antibody and it is tagged with 131I, 124I, to elicit radioactivity towards tumor cells, with specificity for B7H3 antigen. B7-H3, assigned as CD276 is a type I trans-membrane protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. It acts by targeting the CD276 antigen. It was also under development for ovarian cancer and retinoblastoma.
It was under investigation for the treatment of metastatic brain cancer.
Y-mAbs Therapeutics Overview
Y-mAbs Therapeutics(Y-mAbs) is a clinical biopharmaceutical company. It develops and commercializes novel antibody therapeutic products for cancer treatment. The Company technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma. It has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$34.9 million for the fiscal year ended December 2021 (FY2021), an increase of 68.2% over FY2020. The operating loss of the company was US$115.4 million in FY2021, compared to an operating loss of US$119.9 million in FY2020. The net loss of the company was US$55.3 million in FY2021, compared to a net loss of US$119.3 million in FY2020. The company reported revenues of US$12.5 million for the third quarter ended September 2022, an increase of 16.1% over the previous quarter.
Quick View – Omburtamab
|Highest Development Stage|